Fate Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
Fate Therapeutics, a clinical-stage biopharmaceutical company focused on cancer immunotherapies, will present at the 10th Annual SVB Leerink Healthcare Conference on February 25, 2021, at 5:00 p.m. EST. The live webcast can be accessed on the company's website, with an archived version available after the event. Fate specializes in developing first-in-class cellular immunotherapies using its proprietary induced pluripotent stem cell (iPSC) platform, targeting tumor-associated antigens and enhancing existing cancer treatments.
- None.
- None.
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced today that the Company will present at the upcoming 10th Annual SVB Leerink Healthcare Conference on Thursday, February 25, 2021, at 5:00 p.m. EST.
The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website shortly after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. Fate Therapeutics is headquartered in San Diego, CA.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com
FAQ
What is the date and time of Fate Therapeutics' presentation at the SVB Leerink Healthcare Conference?
How can I access the Fate Therapeutics presentation online?
What type of therapies does Fate Therapeutics focus on?
What is ProTmune from Fate Therapeutics?
What is the stock symbol for Fate Therapeutics?
